Innovation Focus La Jolla Pharmaceutical Company is dedicated to the commercialization of innovative therapies for life-threatening diseases, positioning it as a potential partner for organizations seeking advanced medical treatments and specialty pharmaceuticals.
Recent Acquisition The company's recent acquisition by Innoviva for nearly $149 million suggests increasing resources and potential expansion opportunities, making it a promising prospect for strategic partnerships or distribution channels.
Product Portfolio With marketed products such as GIAPREZA and XERAVA, La Jolla offers specialty drugs for critical care and infections, providing avenues for sales representatives to target hospitals and clinics specializing in intensive and infectious disease treatments.
Technological Leverage Utilizing cloud-based tech stacks including AWS and GE Healthcare, La Jolla demonstrates a commitment to innovative digital solutions, indicating openness to collaborations around healthcare technology, data management, and digital health tools.
Financial Growth Potential With revenues between $50M and $100M and significant funding of $111M, La Jolla exhibits financial stability and growth potential, creating opportunities for business development initiatives aimed at expanding product distribution and market reach.
$1M$10M
$50M$100M
$1M
$1M$10MLa Jolla Pharmaceutical Company uses 8 technology products and services including Amazon Web Services, Amazon S3, Amazon CloudFront, and more. Explore La Jolla Pharmaceutical Company's tech stack below.
| La Jolla Pharmaceutical Company Email Formats | Percentage |
| FLast@ljpc.com | 84% |
| First.Last@ljpc.com | 3% |
| Last.First@ljpc.com | 3% |
| First-Last@ljpc.com | 1% |
| FirLast@ljpc.com | 2% |
| LastFir@ljpc.com | 1% |
| FirstLast@ljpc.com | 1% |
| LastFirst@ljpc.com | 1% |
| Last_First@ljpc.com | 1% |
| LastF@ljpc.com | 1% |
| F_Last@ljpc.com | 1% |
| First_Last@ljpc.com | 1% |
Biotechnology ResearchMassachusetts, United States51-200 Employees
La Jolla Pharmaceutical Company, a subsidiary of Innoviva, Inc., is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. La Jolla markets GIAPREZA® (angiotensin II) injection and XERAVA® (eravacycline) for injection. For more information, please visit www.ljpc.com.
Company Overview
Media & News
Funding & FinancialsLa Jolla Pharmaceutical Company has raised a total of $111M of funding over 4 rounds. Their latest funding round was raised on Sep 09, 2015 in the amount of $111M.
La Jolla Pharmaceutical Company's revenue is estimated to be in the range of $50M$100M
Funding & FinancialsLa Jolla Pharmaceutical Company has raised a total of $111M of funding over 4 rounds. Their latest funding round was raised on Sep 09, 2015 in the amount of $111M.
La Jolla Pharmaceutical Company's revenue is estimated to be in the range of $50M$100M
1-888-653-2347 
support@leadiq.com